Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" Martin Shkreli said he still likes the stock. SRPT stock is crashing. See the real-time price action here. Sarepta's Phase 3 ESSENCE study, which tested Amondys 45 and Vyondys 53 as treatments for Duchenne muscular dystrophy, failed to meet its primary endpoint of showing clear benefit over placebo. Read Next: Michae ...